Immune reset: CAR-T therapy takes on autoimmune diseases
NCT ID NCT07193667
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a treatment called CAR-T cell therapy for people with severe autoimmune diseases that haven't responded to other treatments. The therapy uses a patient's own immune cells, modified to target and reset the immune system. Only 3 participants will be enrolled to check safety and whether the approach can reduce symptoms and the need for ongoing medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19 CAR-T cells
- What this could lead to
- If it works, this could offer a way to control severe autoimmune diseases without needing lifelong medication.
- What could go wrong
- This is a very early, tiny trial with only 3 participants, so results may not apply to everyone. CAR-T therapy also carries risks like severe immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOSITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
No. 155, The First Affiliated Hospital of China Medical University, Nanjing North Street, Heping District, Shenyang, Liaoning Province
RECRUITINGShenyang, Liaoning, 110001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?
- Immune clues in the blood may foretell heart trouble
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.
- Can a new drug calm the immune System's attack on blood cells?